U.S. Hospitality Stock News

NasdaqGS:IREN
NasdaqGS:IRENSoftware

IREN (IREN) Earnings Swing To US$384.6 Million Net Income Challenges Bearish Narratives

IREN (IREN) has just put fresh numbers on the table for Q2 2026, with the latest quarter showing total revenue of US$240.3 million and basic EPS of US$1.42, while trailing twelve month revenue sits at US$688.6 million and EPS at US$2.23. Over recent quarters the company has seen revenue move from US$52.8 million and an EPS loss of US$0.27 in Q1 2025, to US$117.9 million and EPS of US$0.09 in Q2 2025, then to US$148.1 million and EPS of US$0.11 in Q3 2025, and further to US$180.6 million with...
NYSE:RAMP
NYSE:RAMPSoftware

LiveRamp (RAMP) EPS Surge To US$0.63 Tests Cautious Growth Narratives

LiveRamp Holdings (RAMP) just posted Q3 2026 results with revenue of US$212.2 million and basic EPS of US$0.63, set against a trailing twelve month picture of US$795.6 million in revenue and EPS of US$1.06. Over recent quarters, the company has seen revenue move from US$185.5 million in Q2 2025 to US$212.2 million in Q3 2026, while quarterly basic EPS shifted from US$0.03 to US$0.63, giving investors a clearer view of how the income statement is scaling. With the business now reporting...
NYSE:SPB
NYSE:SPBHousehold Products

Spectrum Brands Holdings (SPB) One Off Loss Puts Earnings Quality Narratives To The Test

Financial results set the stage for Spectrum Brands Holdings' latest earnings story Spectrum Brands Holdings (SPB) opened Q1 2026 with revenue of US$677 million and basic EPS of US$1.26. This sets a straightforward benchmark for investors weighing the new numbers against the current share price of US$75.72. The company reported quarterly revenue of US$700.2 million and EPS of US$0.87 in Q1 2025, compared with revenue of US$677 million and EPS of US$1.26 in Q1 2026. Over the trailing twelve...
NasdaqGM:SYM
NasdaqGM:SYMMachinery

Symbotic (SYM) Turns Q1 EPS Profit As Bulls And Skeptics Reassess Growth Narrative

Symbotic Q1 2026 earnings in focus Symbotic (SYM) has opened fiscal 2026 with Q1 revenue of US$630.0 million and Basic EPS of US$0.02, setting the tone for how investors assess its path toward sustained profitability. The company has seen revenue rise from US$486.7 million in Q1 2025 to US$630.0 million in Q1 2026, while Basic EPS has shifted from a loss of US$0.03 to a profit of US$0.02 over the same period, giving this quarter a clearer view of how margins are shaping up. See our full...
NYSE:GFF
NYSE:GFFBuilding

Griffon ONCAP Venture Reshapes Tools Brands And Valuation Outlook

Griffon Corporation (NYSE:GFF) has entered a joint venture with ONCAP that combines key brands from both companies. The new entity is intended to be a leading global provider of hand tools, home organization products, and lawn and garden solutions. This move reshapes Griffon’s Consumer and Professional Products business and changes how its brands compete in the global market. For investors watching NYSE:GFF, this joint venture comes with the stock trading around $89.57 and multi year...
NYSE:KD
NYSE:KDIT

Kyndryl AI SAP Expansion And Hertz Deal Raise Long Term Questions

Kyndryl Holdings (NYSE:KD) has launched an SAP Transformations Center of Excellence that uses an AI driven approach to modernize customer systems. The company is working with Nova Intelligence to support AI based transformation services for SAP clients. Kyndryl has also extended its agreement with Hertz to modernize the car rental group's technology using cloud migration and advanced AI frameworks. For investors looking at Kyndryl as a managed infrastructure and IT services provider, these...
NYSE:VRTS
NYSE:VRTSCapital Markets

Virtus Expands Beyond Equities As Valuation Lags And Momentum Weakens

Virtus Investment Partners (NYSE:VRTS) is expanding into private markets through a majority stake in Keystone National Group and a minority investment in Crescent Cove. The firm is also launching new actively managed ETFs as it adjusts its product lineup alongside recent equity outflows. These moves reshape Virtus Investment Partners' business mix beyond its traditional equity focused strategies. For investors watching NYSE:VRTS, the timing of these steps comes after a period of weaker...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Tilray Brands Balances European Medical Push With U.S. Spirits Expansion

CC Pharma, Tilray Brands' European pharmaceutical distribution arm, was named a TOP 100 Innovator in Germany, highlighting its role in medical cannabis and broader pharma distribution. Breckenridge Distillery, a Tilray Brands spirits label, expanded its distribution through a new partnership in Illinois, increasing its presence in the U.S. market. For investors watching NasdaqGS:TLRY, these updates relate to two of the company’s key business lines: medical cannabis in Europe and branded...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

WesBanco (WSBC) Valuation Check After Earnings Miss And Acquisition Integration Update

Why WesBanco’s latest earnings moved the stock WesBanco (WSBC) shares reacted after fourth quarter results met revenue expectations but modestly missed non GAAP earnings, as management discussed acquisition integration, deposit trends, expense actions, and growth plans in newer markets. See our latest analysis for WesBanco. The share price reaction around earnings sits within a stronger recent trend, with a 7 day share price return of 6.02% and a 90 day share price return of 20.87%, while the...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive?

If you are trying to work out whether Iovance Biotherapeutics is a bargain or a value trap at its current share price, you will want a clear view of what the market is actually paying for its future prospects. The stock last closed at US$2.36 and has posted returns of a 10.3% decline over 7 days, 7.5% decline over 30 days, 6.3% decline year to date, 59.9% decline over 1 year, 68.2% decline over 3 years and 95.1% decline over 5 years, which will influence how investors think about its risk...
NYSE:BHC
NYSE:BHCPharmaceuticals

Xifaxan Trial Setback Puts Bausch Health Growth Plans Under Review

Bausch Health Companies (NYSE:BHC) reported a significant setback after a phase 3 clinical trial for Xifaxan failed to support a planned label expansion. The trial aimed to widen approved uses of Xifaxan, a key product in the company’s gastroenterology portfolio. This outcome affects a planned growth avenue and comes as Bausch Health assesses ways to address future patent expiration risks. Bausch Health Companies, known for its diversified portfolio in eye health, gastroenterology and...
NYSE:AB
NYSE:ABCapital Markets

Is AllianceBernstein (AB) Pricing Look Full After Strong Multi‑Year Share Price Gains

If you are wondering whether AllianceBernstein Holding is fairly priced or offering value at its current level, this article walks through the key signals that matter for long term investors. The stock last closed at US$42.36, with reported returns of 2.6% over 7 days, 7.0% over 30 days, 9.6% year to date, 28.4% over 1 year, 36.5% over 3 years and 66.0% over 5 years, which gives useful context before assessing what you are paying for today. Recent share price moves have been covered...
NYSE:SYY
NYSE:SYYConsumer Retailing

A Look At Sysco (SYY) Valuation After Earnings Beat And Strong January Outlook

Sysco (SYY) shares recently moved higher after the company reported quarterly results that aligned with revenue expectations and delivered slightly better adjusted earnings, supported by improving case volumes and disciplined expense control. See our latest analysis for Sysco. The recent earnings beat and upbeat commentary on January trading have been reflected in Sysco’s 30-day share price return of 15.89% and year to date share price return of 16.52%, while the 1-year total shareholder...
NYSE:MA
NYSE:MADiversified Financial

Is Mastercard’s 2025 Earnings Jump and Agent Suite Pivot Altering The Investment Case For MA?

Mastercard recently reported its full-year 2025 results, with sales rising to US$32.79 billion and net income reaching US$14.97 billion, alongside announcing a 4% workforce reduction, a US$200 million restructuring charge and completion of US$8.77 billion in share repurchases under its 2024 buyback authorization. At the same time, Mastercard is pushing further into AI-powered “agentic commerce” through its upcoming Mastercard Agent Suite, highlighting how payments, data services and advisory...
NasdaqGS:SNEX
NasdaqGS:SNEXCapital Markets

StoneX Group Q1 EPS Surge Tests Bullish Narratives On Thin 0.2% Margin

StoneX Group’s Q1 2026 earnings put recent growth in focus StoneX Group (SNEX) opened its new fiscal year with Q1 2026 revenue of about US$38.5b and basic EPS of US$2.75, setting the tone after a year where earnings were reported to have grown 30.7%. The company has seen quarterly revenue move from US$27.6b in Q1 2025 to US$38.5b in Q1 2026, while basic EPS over that stretch ranged from US$1.29 to US$2.75, alongside trailing twelve month EPS of US$7.21 backed by net income of US$349.4m. With...
NYSE:ARDT
NYSE:ARDTHealthcare

Is It Time To Reassess Ardent Health (ARDT) After A 42% One-Year Share Price Fall

If you are wondering whether Ardent Health's current share price reflects its real worth, this article will walk you through what the numbers are saying about value. The stock last closed at US$8.58, with a 4.1% return over the past 7 days, a 7.9% decline over the last 30 days, and a 0.7% decline year to date, compared with a 42.3% decline over the past year. Recent news flow around Ardent Health has largely centered on its position within the US healthcare sector and how investors are...
NYSE:NI
NYSE:NIIntegrated Utilities

A Look At NiSource (NI) Valuation As Shares Trade Near Narrative Fair Value Estimate

NiSource stock overview NiSource (NI) is on investors’ radar after recent trading left the shares at $43.93, with a 1 day return of 0.2% and a 7 day decline of 1.6%. Over the past month the stock shows a 4.9% gain and a 0.9% return in the past 3 months, against a backdrop of annual revenue of $6,327.1 million and net income of $893.5 million. See our latest analysis for NiSource. Recent share price momentum for NiSource has been modest, but the 18.2% 1 year total shareholder return and solid...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Arm’s Record AI Revenue Meets Lofty Valuation And Supply Risks

Arm Holdings (NasdaqGS:ARM) reported record third quarter revenue, supported by demand linked to AI and data center workloads. The company highlighted rapid uptake of its Compute Subsystems as it expands beyond mobile into AI, data center, automotive, and edge computing. Management pointed to new partnerships with major hyperscalers and industry players as a factor in broadening Arm's role in high growth compute markets. Arm also flagged ongoing chip and memory shortages as a potential...
NYSE:DQ
NYSE:DQSemiconductor

Daqo New Energy (DQ) Is Down 8.5% After GLJ Downgrade On China Polysilicon Concerns Has The Bull Case Changed?

In early February 2026, GLJ Research downgraded Daqo New Energy from Buy to Sell, citing concerns over China’s polysilicon supply-demand balance and uneven policy execution intended to curb excess capacity. The firm also projected that Daqo’s net losses could narrow in 2025 compared with 2024, highlighting operational improvement that contrasts with persistent industry headwinds. We’ll now examine how GLJ Research’s downgrade, driven by China’s polysilicon market uncertainties, shapes Daqo...
NYSE:GRC
NYSE:GRCMachinery

Gorman-Rupp Record 2025 Results And Cost Savings Plan Under Review

Gorman-Rupp (NYSE:GRC) reported record net sales, net income, and incoming orders for the full year 2025. The company outlined operational optimization efforts that are expected to bring cost savings and support improved profitability over time. The update highlights both financial performance and changes to the company’s operating footprint that are important for shareholders to monitor. For investors tracking NYSE:GRC, the latest update comes with the stock at $59.55 and a reported 60.4%...
NYSE:PAR
NYSE:PARSoftware

PAR Technology Deepens Restaurant Platform Push With Jack’s And Netchex

PAR Technology (NYSE:PAR) has expanded its partnership with Jack’s Family Restaurants, which will roll out a unified platform for point of sale, payments, loyalty, and hardware across about 300 locations. The company has also broadened its integrations with workforce management provider Netchex, linking restaurant operations more tightly with payroll and HR systems for multi location operators. PAR Technology is leaning into its role as a full stack restaurant tech provider at a time when...
NYSE:TDW
NYSE:TDWEnergy Services

Is It Too Late To Consider Tidewater (TDW) After Recent Share Price Strength?

If you are wondering whether Tidewater's share price still offers value or if most of the opportunity is already priced in, the next sections will walk through what the numbers are suggesting right now. At a last close of US$63.36, Tidewater's returns stand at 1.4% over 7 days, 19.0% over 30 days, 21.3% year to date, 17.6% over 1 year and a very large gain over 5 years. This naturally raises questions about how much upside or risk is currently baked into the valuation. Recent coverage has...
NYSE:CPAY
NYSE:CPAYDiversified Financial

Corpay (CPAY) Margin Slippage Tests Bullish Earnings Growth Narrative

Corpay (CPAY) just posted its FY 2025 results with Q4 revenue of US$1.2b and basic EPS of US$3.81, capped by trailing twelve month revenue of US$4.5b and EPS of US$15.25. The company has seen revenue move from US$1.0b in Q1 2025 to US$1.2b in Q4, while quarterly EPS ranged from US$3.46 to US$4.03 over the year, giving investors a clear view of how the top line and per share profitability have tracked through the fiscal period. With net profit margins easing over the past year, this latest...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Zimmer Biomet (ZBH) Valuation Check As Dividend Strength Meets Softer Long Term Share Performance

Recent focus on Zimmer Biomet Holdings (ZBH) centers on its dividend track record and payout safety, which contrasts with softer recent share returns and has prompted investors to reassess the stock’s income appeal. See our latest analysis for Zimmer Biomet Holdings. At a share price of $88.73, Zimmer Biomet’s near term share price momentum has been mixed. The 7 day share price return is 3.15%, but the 30 day share price return shows a 6.35% decline. Longer term total shareholder returns over...